Baird lowered the firm’s price target on Cencora to $283 from $287 and keeps an Outperform rating on the shares. The firm updated its guidance raising full-year 2024 earnings guidance for the fifth time. Off a higher FY24 base, FY25 initial outlook is expected at low end of LRP targets due to COVID-related comps and potential loss of FCS to be acquired in June 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora Announces EPS Forecast and Evernorth Contract Renewal
- TD Cowen sees ‘minimal’ impact to Cencora FY25 EPS from Cigna change
- Cencora Enhances Governance and Executive Compensation Structures
- Cencora Expands Board, Announces New Member Appointments
- Walgreens sells shares of Cencora for roughly $1.1B of proceeds
Questions or Comments about the article? Write to editor@tipranks.com